Joseph Walewicz

Joseph Walewicz is currently Director at NeuPath Health, Inc. since 2026.
Former positions include Independent Director at Warnex, Inc. from 2011 to 2014; Executive Director of Equity Research at CIBC World Markets, Inc. from 2005 to 2008; Director at Klinik Health Ventures Corp.; Equity Research Associate of Biotechnology at Lehman Brothers, Inc.; Vice President at Paladin Labs, Inc. from 2009 to 2011; Vice President of Equity Research at BMO Nesbitt Burns, Inc. (US); Vice President & Senior Health Care Analyst at Orion Securities, Inc. from 2004 to 2005; Vice President-Business & Corporate Development at Mirati Therapeutics, Inc. from 2011 to 2013; Healthcare Analyst at Laurentian Bank Securities, Inc. from 2014 to 2017; Member at Licensing Executives Society USA & Canada, Inc.; Executive VP-Business & Corporate Development at Clementia Pharmaceuticals, Inc. from 2017 to 2019; and Chief Financial Officer at Fibrocor Therapeutics, Inc. from 2021 to 2022.
Education includes an MBA from McGill University and an undergraduate degree from Queen's University.